secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-138915
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts IND for first neoantigen-directed T-cell therapy from Adaptive-Genentech collaboration
--------------------------------------------------------------------------------

- FDA accepted IND for TCR-based T-cell therapy candidate; first from collaboration to enter clinical development.
- Therapy targets neoantigens identified via Adaptive's TCR discovery platform.
- Genentech responsible for clinical, regulatory, and commercialization efforts.
- Adaptive reaffirms FY2023 revenue guidance of $205-215 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312523138915/0001193125-23-138915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312523138915/d420874d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-138915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer